Barco, S., Lavarello, C., Cangelosi, D., Morini, M., Eva, A., Oneto, L., . . . Cangemi, G. (2022). Untargeted LC-HRMS Based-Plasma Metabolomics Reveals 3-O-Methyldopa as a New Biomarker of Poor Prognosis in High-Risk Neuroblastoma. Frontiers Media S.A.
Chicago Style (17th ed.) CitationBarco, Sebastiano, et al. Untargeted LC-HRMS Based-Plasma Metabolomics Reveals 3-O-Methyldopa as a New Biomarker of Poor Prognosis in High-Risk Neuroblastoma. Frontiers Media S.A, 2022.
MLA (9th ed.) CitationBarco, Sebastiano, et al. Untargeted LC-HRMS Based-Plasma Metabolomics Reveals 3-O-Methyldopa as a New Biomarker of Poor Prognosis in High-Risk Neuroblastoma. Frontiers Media S.A, 2022.
Warning: These citations may not always be 100% accurate.